KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Receivables (2017 - 2025)

Novartis Ag (NVS) has disclosed Receivables for 9 consecutive years, with $10.1 billion as the latest value for Q4 2025.

  • Quarterly Receivables rose 18.29% to $10.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.1 billion through Dec 2025, up 18.29% year-over-year, with the annual reading at $10.1 billion for FY2025, 18.29% up from the prior year.
  • Receivables hit $10.1 billion in Q4 2025 for Novartis Ag, up from $8.5 billion in the prior quarter.
  • In the past five years, Receivables ranged from a high of $10.1 billion in Q4 2025 to a low of $8.4 billion in Q4 2023.
  • Historically, Receivables has averaged $9.0 billion across 5 years, with a median of $8.8 billion in 2021.
  • Biggest five-year swings in Receivables: fell 7.37% in 2023 and later grew 18.29% in 2025.
  • Year by year, Receivables stood at $8.8 billion in 2021, then increased by 2.57% to $9.0 billion in 2022, then decreased by 7.37% to $8.4 billion in 2023, then rose by 1.93% to $8.5 billion in 2024, then rose by 18.29% to $10.1 billion in 2025.
  • Business Quant data shows Receivables for NVS at $10.1 billion in Q4 2025, $8.5 billion in Q4 2024, and $8.4 billion in Q4 2023.